Additionally, identifying cancer types sensitive to combination treatments and optimizing combination dosages are key to the successful clinical application of combined PARPi and ATRi therapy in BRCA1/2 wild-type cancer patients, necessitating further large-scale studies. This evidence concerns the gene BRCA1 and cancer.